In contrast, the only solid tumors with noticeable sensitivity to venetoclax were SCLC and MYCN-amplified neuroblastoma [13,35,36], and there is an on-going clinical trial with venetoclax for neuroblastoma (NCT04029688). The gene discussed is MYCN; the disease is neuroblastoma.